Logo

Merck & Co. Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 Study for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Canc

Share this
Merck & Co. Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 Study for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Canc

Merck & Co. Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 Study for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Canc

Shots:

  • The P-III KEYNOTE-177 study involves assessing of Keytruda as monothx. vs SOC CT (mFOLFOX6/ FOLFIRI- with/out bevacizumab/ cetuximab) as a 1L treatment in 308 patients with MSI-H or dMMR advanced colorectal cancer
  • The P-III KEYNOTE-177 study resulted in meeting its one of its dual 1EPs i.e. demonstrated significant improvement in PFS. Following the DMC’s recommendation- the study will continue without changes to evaluate OS- the other dual 1EP
  • Keytruda is an anti-PD-1 therapy- act by blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 thus activates T lymphocytes affecting both tumor and healthy cells and has received FDA’s approval as the first therapy for use on a biomarker- regardless of tumor type- in prior treated patients with MSI-H or dMMR solid tumors in May’2017

Click here ­to­ read full press release/ article

Ref: Merck & Co. | Image: Lucky Step


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions